The FDA Panel That Might Regulate Itself Into a Payday
The FDA is about to let a panel of peptide-selling doctors and pharmacists vote on whether their own products should be legal. Critics say the July advisory committee meeting is a case study in regulatory capture, with billions in gray-market sales hanging in the balance.
Imagine you're picking a jury for a shoplifting trial, and half the jurors own the store. That's roughly what critics say is happening at the FDA right now.
The agency's Pharmacy Compounding Advisory Committee (PCAC) is set to meet July 23–24 to decide whether seven popular peptides should be cleared for broader use by compounding pharmacies. The problem? A majority of the newly appointed panel members run clinics, pharmacies, or businesses that sell the very peptides they're about to vote on.
The Peptides on Trial
First, some quick context. Peptides are short chains of amino acids (think of them as protein fragments) that have exploded in popularity among wellness and anti-aging crowds. Names like BPC-157, TB-500, and MOTS-c are whispered about in biohacker forums and longevity clinics the way people used to talk about creatine in the '90s.
The FDA has kept most of these peptides off the approved compounding list, citing thin safety data and concerns about impurities. The agency's own scientists reportedly recommend against listing these seven peptides for widespread compounding. Their briefing documents flag risks including immunogenicity (your immune system attacking the peptide) and toxicity from impurities.
But none of that stopped the meeting from being scheduled. And none of it stopped a very particular group of people from being seated on the panel.
Meet the New Panel
The PCAC had six vacancies earlier this year, including the chair and consumer representative slots. Those seats got filled fast, and the new roster reads less like a scientific advisory board and more like a peptide industry trade conference.
Consider the lineup. Gabriel Alizaidy is the scientific director at Maximus Health, a company offering GLP-1 microdosing and peptide therapies. He promotes peptides like BPC-157 on social media and sells paid consultations on peptide use. Haleem Mohammed operates Gameday Men's Health, a chain of Florida clinics distributing peptides, testosterone, and weight-loss meds. runs Makena Health in Hawaii, a functional medicine clinic offering peptide therapy packages.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Joshua Starbuck
Then there's Bobby Harshbarger III, a Tennessee state senator and pharmacist whose Premiere Pharmacy offers compounded medications for weight management and longevity. His mother, Rep. Diana Harshbarger (R-Tenn.), sent a letter directly to HHS Secretary Robert F. Kennedy Jr. urging him to relax peptide restrictions. The son now sits on the panel that could make that happen.
Kris Wusterhausen prescribes peptides through his Texas clinic and holds an "Elite Practitioner" designation at Prodrome Science. Melissa Loseke runs a wellness clinic offering hormone replacement and peptide-adjacent services. Gerald Morris works at a clinic that offers ipamorelin, one of the peptides previously restricted by the FDA.
The holdover members, people like Elizabeth Rebello from MD Anderson Cancer Center and Brian Serumaga from the U.S. Pharmacopeia, are now outnumbered.
The Kennedy Connection
This meeting didn't materialize out of thin air. It traces back to April 15, 2026, when HHS Secretary Kennedy directed the FDA to remove 12 peptides from "Category 2," the classification that had effectively banned their use in compounding. That directive forced the agency to schedule the July PCAC review.
Kennedy has been vocal about wanting to "make peptides more accessible," including on popular podcasts. His broader regulatory philosophy (visible in his wholesale replacement of all 17 members of the CDC's vaccine advisory committee in June 2025) favors what he calls "individual choice" over population-level mandates.
No reporting has confirmed that Kennedy personally selected these PCAC members or that they're formal political allies. But the pattern is hard to ignore: Kennedy creates the policy conditions, vacancies get filled with people who benefit from the policy outcome, and the panel votes.
Why "Removed from Category 2" Doesn't Mean What You Think
One critical nuance is getting lost in the hype. When the FDA removed 12 peptides from Category 2 in April 2026, peptide enthusiasts celebrated like their team won the Super Bowl. But removal from Category 2 does not equal approval.
The FDA uses three categories for bulk drug substances. Category 1 means the FDA generally does not intend to take enforcement action against compounding if other conditions are met. Category 2 means it poses significant safety concerns and can't be compounded. Category 3 means the substance was nominated with insufficient supporting information for FDA evaluation.
Most of those 12 peptides, including BPC-157 and injectable GHK-Cu, landed in regulatory limbo. They're no longer banned, but they're not approved either. Legal analyses confirm that compounding pharmacies still lack a lawful basis to use them for human patients. The July meeting is the next domino: if the PCAC recommends adding these peptides to the 503A bulk drug substances list, that could finally open the door.
The Gray Market Lurking in the Background
All of this plays out against a booming underground. The U.S. gray-market peptide industry runs an estimated $250–300 million annually, with imports from international pharmacies reportedly jumping 70% between 2024 and 2025. Vendors slap "research use only" labels on products clearly marketed for human injection. Crypto-enabled peptide sales hit a $100 million annual run rate in 2026, according to on-chain estimates.
Supporters of broader access argue that clearer rules will pull users out of this sketchy ecosystem and into regulated medical channels. That's not a crazy argument. But critics counter that loosening restrictions without robust clinical data just puts a government stamp on substances that haven't earned it.
Former FDA official Dr. Peter Lurie, now at the Center for Science in the Public Interest, called the idea of letting largely untested peptides flow through compounding channels a "profound threat" to the drug-vetting system. His worry: if compounding becomes commercially attractive enough, companies will have every incentive to skip Phase III trials entirely.
What Happens Next
The PCAC meets July 23–24. If the panel votes to recommend these peptides for the 503A list, the FDA would then need to formally add them through the Federal Register. That process takes time, but the political pressure is enormous.
Five more peptides are already scheduled for PCAC review before February 2027. Public health groups, including Public Citizen, are pushing back hard, urging the FDA to require full drug approval with real clinical trials instead of the compounding shortcut.
The deeper question isn't really about peptides at all. It's about whether advisory committees are supposed to be guardrails or rubber stamps. If a panel stacked with people who profit from a "yes" vote delivers that yes, it won't just open the door for BPC-157. It'll set a template for how regulatory decisions get made in this administration, on vaccines, supplements, and anything else where ideology and commerce intersect.
The jury, in other words, is very much still out. It's just that some of them own the store.
Funding & Financings6 min read
Wall Street's Biggest Names Just Bet $1 Billion on One Biotech
Sixth Street and KKR just injected $1 billion of preferred equity into BridgeBio Pharma, one of the largest such deals ever for a public biotech. The unusual structure reveals a new financing playbook for late-stage drug companies caught between clinical success and commercial scale.
